Gastrointestinal Very common (10% or more): Gastrointestinal adverse reactions (up to 73%), nausea (up to 44%), vomiting (up to 36%), diarrhea (up to 30%), constipation (up to 24.2%), abdominal pain (up to 20%) Common (1% to 10%): Dyspepsia, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, viral gastroenteritis, increased amylase, increased lipase, dry mouth, severe gastrointestinal adverse reactions, delayed gastric emptying Uncommon (0.1% to 1%): Acute pancreatitis, appendicitis Frequency not reported : Hemorrhoids, hiccups Postmarketing reports : Ileus, intestinal obstruction, severe constipation, hiccups, acute pancreatitis, necrotizing pancreatitis In clinical trials in adults using the subcutaneous injection for weight reduction, 73% of treated patients reported gastrointestinal adverse reactions, including severe reactions (4.1%)

The Takeaway This sub-analysis confirms that semaglutides cardiac benefits happen quickly and build-up over time, with the eventual extra weight loss further intensifying them
Semaglutide and Nt-Probnp in Obesity-Related Hfpef: Insights from the step-Hfpef program
This suggests that APTF-2 controls glp-1 expression and function by directly interacting with the conserved TFAP2 binding site
FAQs Here are answers to some common questions our therapist at Therapy Fleet receives about semaglutide to suppress appetite